Daclatasvir/Sofosbuvir/Ribavirin
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Daclatasvir/Sofosbuvir/Ribavirin, covering 2019-04-24 to 2019-04-24. Get the full timeline:
Most recent: Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics [Phase 4]